Search Close Search
Page Menu

Recent Publications

Publications from 2017 to present 

  1. Hamada, K., & Fan, X. (2020). The impact of COVID-19 on individuals living with serious mental illness. Schizophr Res. doi:10.1016/j.schres.2020.05.054
  2. Li, H., Ou, Y., Liu, F., Chen, J., Zhao, J., Guo, W., & Fan, X. (2020). Reduced connectivity in anterior cingulate cortex as an early predictor for treatment response in drug-naive, first-episode schizophrenia: A global-brain functional connectivity analysis. Schizophr Res, 215, 337-343. doi:10.1016/j.schres.2019.09.003
  3. Yang Y, Zhang L, Guo D, Zhang L, Yu H, Liu Q, Su X, Shao M, Song M, Zhang Y, Ding M, Lu Y, Liu B, Li W, Yue W, Fan X, Yang G, Lv L. Association of DTNBP1 with Schizophrenia: Findings From Two Independent Samples of Han Chinese Population. Frontiers in Psychiatry, in press.
  4. Worthington, M. A., Petkova, E., Freudenreich, O., Cather, C., Holt, D., Bello, I., . . . Goff, D. C. (2020). Air pollution and hippocampal atrophy in first episode schizophrenia. Schizophr Res, 218, 63-69. doi:10.1016/j.schres.2020.03.001
  5. Oh, S. J., & Fan, X. (2020). Current understanding on the role of nitric oxide and therapeutic potential of NO supplementation in schizophrenia. Schizophr Res. doi:10.1016/j.schres.2020.05.050
  6. Oh, S. J., & Fan, X. (2019). The Possible Role of the Angiotensin System in the Pathophysiology of Schizophrenia: Implications for Pharmacotherapy. CNS Drugs, 33(6), 539-547. doi:10.1007/s40263-019-00632-4
  7. Zhang L, Bao J, Harrington A, Fan X, Ning Z, Zhang J, Hu M, Zhou Z, Cai Z, Zhao M, Du J. Mixed methods to explore factors associated with the decline of patients in the Methadone Maintenance Treatment program in Shanghai, China. Harm Reduction Journal, 2019; 16(1):34. doi: 10.1186/s12954-019-0304-8. PMID: 31133016.
  8. Li H, Guo W, Liu F, Cheng J, Su Q, Zhang Z, Fan X, Zhao J. Enhanced baseline activity in the left ventromedial putamen predicts individual treatment response in drug-naïve, first episode schizophrenia: results from two independent study samples. EBioMedicine, 2019; 46, 248-255. PMID: 31307956.
  9. Chiang M, Du J, Lombardi D, Harrington A, Shukair N, Zhao M, Fan X. Methamphetamine-associated psychosis: clinical presentation, biological basis and treatment options. Human Psychopharmacology: Clinical and Experimental, in press. PMID: 31441135.
  10. Wei Q, Yao Y, Qiu Y, Cui J, Li L, Zhang J, Guan N, Fan X. Research training as part of psychiatry residency training in North America: implications for psychiatry residency training in China. Chinese Journal of Medical Education, in press.
  11. Wu R, Ou Y, Guo W, Liu F, Chen J, Li H, Fan X, Zhao J. Reduced brain activity in the right putamen as an early predictor for treatment response in drug-naïve, first episode schizophrenia. Frontiers in Psychiatry, in press.
  12. Oh S, Fan X. Role of the angiotensin system in the pathophysiology of schizophrenia: implications for pharmacotherapy. CNS Drugs, 2019; 33, 539-547. PMID: 30993607.
  13. Chiang M, Reid-Varley WB, Fan X. Creative art therapy for mental illness. Psychiatry Research, 2019; 275, 129-136. PMID: 30901671.
  14. Zhuo K, Tang Y, Song Z, Wang Y, Wang J, Qian Z, Li H, Mei L, Zhu D, Xiang Q, Chen T, Yang Z, Xu Y, Fan X, Wang J, Liu D. Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial. Neuropsychiatric Disease and Treatment, 2019; 15, 1141-1150. PMID: 31190822.
  15. Liu Y, Zhao J, Fan X, Guo W. Dysfunction in serotonergic and noradrenergic systems and somatic symptoms in psychiatric disorders. Frontiers in Psychiatry, 2019; 10:286.doi: 10.3389/fpsyt.2019.00286. PMID: 31178761.
  16. Robertson I, Cheung A, Fan X. Insomnia in patients with schizophrenia: current understanding and treatment options. Progress in Neuropsychopharmacology and Biological Psychiatry, 2019; 92, 235-242. PMID: 30707986.
  17. Wu C, Chiang M, Fusaro-Davis M, Cimpeanu C, Harrington A, Fan X. Lifestyle education for patients with severe mental illness during their psychiatric inpatient stay. Asian Journal of Psychiatry, 2019; 40, 15-17. PMID: 30673623.
  18. Fan X, Copeland P, Shukair N, Harrington A, Freudenreich O, Goff D, Henderson D. Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo-controlled trial. Psychopharmacology (Berlin), 2019, 236, 1949-1957. PMID: 30747254.
  19. Brown H, Freudenreich O, Fan X, Heard S, Goff D, Petrides G, Harrington A, Kane JM, Judge H, Hoeppner B, Fava M, Perlis RH. Intravenous sodium nitroprusside treatment for outpatients with schizophrenia: a randomized clinical trial. JAMA Psychiatry, 2019; 76, 691-699. PMID: 30916714.
  20. Goff D, Freudenreich O, Cather C, Holt D, Bello I, Diminich E, Tang Y, Ardekani B, Worthington M, Zeng B, Wu R, Fan X, Li C, Troxel A, Wang J, Zhao J. Citalopram in first episode schizophrenia: the DECIFER trial. Schizophrenia Research, 2019; 208, 331-337. PMID: 30709746.
  21. Li X, Tian X, Lv L, Hei G, Huang X, Fan X, Zhang J, Zhang J, Pang L, Song X. Microglia activation in the offspring of prenatal Poly I:C exposed rats: a PET imaging and immunohistochemistry study. General Psychiatry, 2018; 31(1):e000006. doi: 10.1136/gpsych-2018-000006. PMID: 30582116.
  22. Guo W, Liu F, Cheng J, Su Q, Zhang Z, Li H, Zhu F, Fan X, Zhao J. Disrupted asymmetry of inter- and intra-hemispheric functional connectivity in patients with drug-naive, first-episode schizophrenia and their unaffected siblings. EBioMedicine, 2018; pii: S2352-3964(18)30370-0. PMID: 30241918.
  23. Yuan X, Zhang P, Wang, Y, Liu Y, Li X, Kumar B, Hei G, Lv L, Huang X, Fan X, Song X. Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia. Schizophrenia Research, 2018; 201, 299-306. PMID: 29859859.
  24. Wu C, Chiang M, Harrington A, Kim S, Ziedonis D, Fan X. Racial Disparity in Mental Disorder Diagnosis and Treatment between Non-Hispanic White and Asian American Patients in a General Hospital. Asian Journal of Psychiatry, 2018; 34, 78-83. PMID: 29674132.
  25. Liu F, Lv H, Ye Q, Xu X, Fan X, Zhao J. A comprehensive treatment approach for first episode schizophrenia: Introduction and adaptation of the NAVIGATE model in China. Chinese Journal of Psychiatry, 2018; 51, 273-277.
  26. Liu F, Zhang B, Xie L, Ruan Y, Xu X, Zeng Y, Messina L, Zhang J, Fan X. Changes in plasma levels of nitric oxide metabolites and negative symptoms after 16-week minocycline treatment in patients with schizophrenia. Schizophrenia Research, 2018; 199, 390-394. PMID: 29526457.
  27. Goff D, Zeng B, Ardekani B, Diminich E, Tang Y, Fan X, Galatzer-Levy I, Li C, Troxel A, Wang J. Association of hippocampal atrophy with duration of untreated psychosis and molecular biomarkers during initial antipsychotic treatment of first episode psychosis. JAMA Psychiatry, 2018; 75, 370-378. PMID: 29466532.
  28. Luo Y, Liu F, Natarajan R, Shukair N, Copeland P, Fan X. Salsalate as an adjunctive treatment for psychopathology and cognition in patients with schizophrenia: a proof of concept study. International Clinical Psychopharmacology, 2018; 33, 88-91. PMID: 29084087.
  29. Liu F, Xie L, Zhang B, Ruan Y, Zeng Y, Xu X, Zhao J, Fan X. No effect of adjunctive minocycline treatment on body metabolism in patients with schizophrenia. Journal of Clinical Psychopharmacology, 2018; 38, 125-128. PMID: 29424804.
  30. Lyu X, Du J, Zhan, G, Wu Y, Su H, Zhu Y, Jarskog F, Zhao M, Fan X. Naltrexone and bupropion combination treatment for smoking cessation and weight loss in patients with schizophrenia. Frontiers in Pharmacology, 2018; 9:181. doi: 10.3389/fphar. PMID: 29563871.
  31. Ruan X, Zhong N, Yang Z, Fan X, Zhuang W, Du J, Jiang H, Zhao M. Gray matter volume showed dynamic alterations in methamphetamine users at 6 and 12 months abstinence: a longitudinal voxel-based morphometry study. Progress in Neuropsychopharmacology and Biological Psychiatry, 2018; 81, 350-355. PMID: 28887180.
  32. Wang S, Zhang Y, Lv L, Wu, R, Fan X, Zhao J, Guo W. Abnormal regional homogeneity as a potential imaging biomarker for adolescent-onset schizophrenia: a resting-state fMRI study and support vector machine analysis. Schizophrenia Research, 2018; 192, 179-184. PMID: 28587813.
  33. Fan X, Song X, Jarskog, F, Natarajan R, Shukair N, Freudenreich O, Henderson D, Goff D. The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia. Acta Psychiatrica Scandinavica, 2017; 136, 465-472. PMID: 28851055.
  34. Mitra S, Natarajan R, Ziedonis D, Fan X. Antioxidant and anti-inflammatory nutrient status, supplementation, and mechanisms in patients with schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry, 2017; 78, 1-11. PMID: 28499901
  35. Zhao Z, Huang T, Tang C, Ni K, Pan X, Yan C, Fan X, Xu D, Luo Y. Altered Resting-State Intra- and Inter- Network Functional Connectivity in Patients with Persistent Somatoform Pain Disorder. PLoS One, 2017; 12(4):e0176494. doi: 10.1371/journal.pone.0176494. PMID:28453543.
  36. Wang Y, Tang W, Fan X, Zhang J, Geng D, Jiang K, Zhu D, Song Z, Xiao Z, Liu D. Resting-state functional connectivity changes within the default mode network and the salience antipsychotic treatment in early-phase schizophrenia. Neuropsychiatric Disease and Treatment, 2017. 13:397-406. doi:10.2147/NDT. S123598. PMID: 28223812.
  37. Pang L, Kennedy D, Wei Q, Lv L, Gao J, Li H, Quan M, Li X, Yang Y, Fan X, Song X. Decreased functional connectivity of insular cortex in drug naïve first episode schizophrenia: in relation to symptom severity. PLoS One, 2017; 12(1):e0167242. doi: 10.1371/journal.pone.0167242. PMID: 28107346.
  38. Liu D, Ji C, Zhuo K, Song Z, Wang Y, Mei L, Zhu D, Xiang Q, Chen T, Yang Z, Zhu G, Wang Y, Cheung E, Xiang Y, Fan X, Chan R, Xu Y, Jiang K. Impaired cue identification and intention retrieval underlie prospective memory deficits in patients with first-episode schizophrenia. Australia and New Zealand Journal of Psychiatry, 2017; 51, 270-277. PMID: 27004487.